In the first 30 months of the project, we have synthesised a variety of probes to meet our objectives, and we have started to evaluate the biological activities of the synthesised probes. For the first work package, we have synthesised peptide sequences that we hypothesise should localise specifically to the cilium. In order to be able to validate this, we have implemented a new fluorescence microscopy based assay for the study of ciliary uptake of small molecules. Using this assay, we have been able to validate some of our constructs, and current work is aimed at proving the mechanism by which the peptides are transported. For this, we have generated cells that lack an essential protein for transport, and we are now studying if there is indeed hampered ciliary uptake of our peptides in these mutant cells. In addition, we have expressed this protein in vitro so that we can study the binding of the peptides using fluorescence polarization assays.
For the second work package, we have synthesised many different peptides that can be used in a reaction with an enzyme to label proteins. We have used these peptides successfully to label a model protein (green fluorescent protein) in vitro. We have cloned all the constructs to express the enzyme in cells, and our next steps are to perform the reaction in cells. As a requirement for this is that the synthetic peptides reach the cytoplasm, we are also evaluating their cell permeability properties, and adjusting these when needed by the incorporation of cell penetrating motifs.
For the final work package we have established a successful synthetic route towards modified coenzyme A constructs that we want to use to label cellular structures. We have generated substrate peptides, expressed the enzyme and are now studying enzymatic activity using our peptides. Our preliminary results show that the enzyme does not have much room to accommodate the synthetic cofactors, and so we are currently moving into the generation of enzyme mutants with expanded binding pockets. As a second objective, we have successfully generated bisubstrate inhibitors of the enzyme, consisting of a covalently linked coenzyme A and substrate peptide, which are currently being evaluated in vitro.